FdaApplication
BLA 761232
Identifiers
- fda_app_no: BLA761232
Properties
| Property | Value |
|---|---|
| applicant_name | BeOne Medicines USA, Inc. |
| application_type | BLA |
| approval_date | 2024-03-13 |
Revenue by product
TEVIMBRA
| Period | Revenue |
|---|---|
| Q2 2026 | $228.5M |
| Q2 2025 | $193.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TEVIMBRA | TISLELIZUMAB-JSGR | 100MG/10ML (10MG/ML) | Injection |
| TEVIMBRA | — | 150MG/15ML (10MG/ML) | Injection |
2 products